Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Locana raises $55 million for RNA editing
by Ryan Cross
May 31, 2019
| A version of this story appeared in
Volume 97, Issue 22
Locana, a start-up that is developing CRISPR-based therapies that target and edit RNA, has raised $55 million in series A financing. The company was cofounded by University of California, San Diego, scientist Gene Yeo in 2016 after his lab reprogrammed CRISPR-Cas9 to cut RNA instead of DNA. That strategy could be used to destroy disease-causing RNA transcripts in conditions like amyotrophic lateral sclerosis and Huntington’s disease. Yeo says Locana is now looking beyond CRISPR for RNA-binding proteins that could be engineered for making RNA-editing therapies.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter